Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $196 from $194 and keeps an Overweight rating on the shares, noting that Auvelity Q3 sales were about 6% above consensus expectations. After updating the firm’s model for the quarter, the firm slightly increased FY25 estimates for Auvelity and Sunosi given Q3 beats, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $178 from $176 at BofA
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
- Axsome Therapeutics files automatic mixed securities shelf